GRISACTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Grisactin, and what generic alternatives are available?
Grisactin is a drug marketed by Wyeth Ayerst and is included in four NDAs.
The generic ingredient in GRISACTIN is griseofulvin, ultramicrocrystalline. There is one drug master file entry for this compound. Additional details are available on the griseofulvin, ultramicrocrystalline profile page.
US Patents and Regulatory Information for GRISACTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | GRISACTIN | griseofulvin, microcrystalline | CAPSULE;ORAL | 050051-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Wyeth Ayerst | GRISACTIN ULTRA | griseofulvin, ultramicrocrystalline | TABLET;ORAL | 062438-002 | Nov 17, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Wyeth Ayerst | GRISACTIN ULTRA | griseofulvin, ultramicrocrystalline | TABLET;ORAL | 062178-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Wyeth Ayerst | GRISACTIN | griseofulvin, microcrystalline | CAPSULE;ORAL | 050051-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
